SEC Form 4 · accession 0001209191-19-014613
GLOBUS MEDICAL INC · GMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
James R Tobin
Director
Period of report
Feb 26, 2019
Accepted (ET)
Feb 28, 2019 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001237831
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Common Stock | Feb 26, 2019 | M | 8,900 | $24.75 | A | 8,900 | D | |
| Class A Common StockF1 | Feb 26, 2019 | S | 8,500 | $47.06 | D | 400 | D | |
| Class A Common Stock | Feb 26, 2019 | S | 400 | $47.91 | D | 0 | D | |
| Class A Common Stock | Feb 28, 2019 | M | 6,100 | $24.75 | A | 6,100 | D | |
| Class A Common Stock | Feb 28, 2019 | M | 20,000 | $25.52 | A | 26,100 | D | |
| Class A Common Stock | Feb 28, 2019 | M | 2,000 | $26.27 | A | 28,100 | D | |
| Class A Common StockF2 | Feb 28, 2019 | S | 18,800 | $48.10 | D | 9,300 | D | |
| Class A Common Stock | Feb 28, 2019 | S | 9,300 | $47.04 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy Class A Common Stock)F3 | $24.75 | Feb 26, 2019 | M | 8,900 | D | — | Aug 28, 2025 | Class A Common Stock | 8,900 | 6,100 | D |
| Stock Option (Right to Buy Class A Common Stock)F3 | $24.75 | Feb 28, 2019 | M | 6,100 | D | — | Aug 28, 2025 | Class A Common Stock | 6,100 | 0 | D |
| Stock Option (Right to Buy Class A Common Stock)F4 | $25.52 | Feb 28, 2019 | M | 20,000 | D | — | Jan 25, 2026 | Class A Common Stock | 20,000 | 0 | D |
| Stock Option (Right to Buy Class A Common Stock)F5 | $26.27 | Feb 28, 2019 | M | 2,000 | D | — | Jan 30, 2027 | Class A Common Stock | 2,000 | 23,000 | D |
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.83 to $47.56, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.00 to $48.33, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- F3These options were granted on August 28, 2015, and vested over a three-year period with one-twelfth (1/12) of the options granted vesting on December 31, 2015, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters.
- F4These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2016, and the balance of the options vesting ratably on a quarterly basis over the following 11 quarters.
- F5These options vest over a three-year period with one-twelfth (1/12) of the options granted vesting on March 31, 2017, and the balance of the options granted vesting ratably on a quarterly basis over the following 11 quarters.